anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention belongs to a Chinese patent medicine for treating bone retrograde affection. Through clinical research for years, the pathogenic mechanisms of bone retrograde affection are held, and the clinical manifestation belongs to small joint disease or named as small joint functional disorder. The theory of the treatment of both symptoms and root causes of diseases of traditional Chinese medicine is adopted, and the present invention takes effects on 'evil repletion positive weakness'. The formula of the present invention has the functions of activating blood circulation to dissipate blood stasis, expelling wind, eliminating cold, regulating qi-flowing for relieving pain, invigorating the kidney, strengthening the bones for generating pith and inhibiting hyperosteogeny. The formula comprises cholera of sheep, rhizoma cibotii, prepared rhizome of rehmannia, rhizoma drynariae, cistanche salsa, suberect spatholobus, safflower, corydalis tuber and sugar or honey as assistance. The effective rate of the present invention is 95.4%, and the cure rate is 87.2%. Common symptoms can be cured for 20 days, serious symptoms can be obviously lightened, and the present invention can prevent the states of illness from relapsing.
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide. (D'Alton 2020). It is estimated that 14 million cases of PPH occur each year worldwide (Rath, 2011). In the United States, PPH causes up to 12% of maternal deaths and is the leading cause of death occurring on the day of delivery (ACOG 2017; Butwick 2019; Evensen 2020; Hawkins 2020). According to the American College of Obstetricians and Gynecologists (ACOG), between 54% and 93% of PPH-associated mortality may be preventable while 70-80% of PPH is due to abnormal uterine tone (atony) (ACOG 2017). Atony involves a deficient response to physiological signals that promote uterine contraction and blood vessel compression after delivery. Contraction of the myometrium compresses the blood vessels supplying the placental bed and thereby causes mechanical hemostasis. Uterine atony following CD is a relatively common problem in the non-laboring patient because contraction of the myometrium is almost entirely absent. Restoring uterine tone can be addressed through 1) medication, 2) surgery, or 3) mechanical means.Post-partum unrecognized uterine hemorrhage due to a closed or narrow cervix that allows blood to collect in a patient undergoing a CD could lead to complications such as dangerously low blood pressure. The DAISY drain is intended to provide a channel through the cervix for fluid drainage after pelvic surgery. The DAISY device consists of a soft silicone drainage tube (proximal end) attached to a semi-flexible catheter, inserted through the hysterotomy created at the time of the CD. The DAISY drain will be placed intraoperatively after delivery of the placenta, stabilization of the patient, and cleansing of the uterine cavity but prior to closure of the hysterotomy. The drain will be placed through the hysterotomy and threaded through the cervix and vaginal canal, out the introitus, so the distal end is accessible outside of the body. In this study, The Drain will be placed on continuous suction according to the IFU for the first two postpartum hours or more if required. At the end of the 2-hour period, the uterus will be evaluated by manual palpation and abdominal ultrasound. The abdominal ultrasound will be performed to document device placement and to assess uterine involution, approximate uterine size and uterine cavity size, presence of intrauterine clots or retained products of conception. The trained user will remove the drain after at least two hours post CD based on clinical management. Suction will be discontinued, and the participant observed for 30 minutes before removal. One method of determining if the drain is no longer needed is by checking and documenting uterine tone. If uterine tone has returned to normal as assessed by palpation, the DAISY drain may be removed.
A process for the stabilization of bacteriophages comprises making virulent strains of bacteriophages by successive activation passages over microbial cultures and treating the strains to make them thermoresistant e.g. to a temperature of 60 DEG C.  A quantity of a salt e.g. sodium chloride, of the order of 5 gm. per litre and an alkaline material e.g. potash, is added to an appropriate culture medium e.g. meat extract, and a sterile solution of bacteriophages is prepared from the strains and culture medium.  A salt e.g. sodium chloride, is added to the sterile solution to a concentration of about 50 gm. per litre, the solution is concentrated e.g. to about one fifth of the original volume, by evaporation in a vacuum at a temperature lower than the maximum temperature to which the virulent strains have been rendered thermoresistant e.g. 55 DEG C., and then tyndallized.
An observational study that uses a digital system to collect physiological, physical and behavioral data using worn sensors on psychiatric patients suffering from schizophrenia, bipolar and schizoaffective disorders. It is a known fact that patients suffering from these disorders are more prone to changes in their mental health condition. Sometimes this change is due to change in medical treatment(whether it was the doctor's decision or low adherence to medication treatment).The mental health condition influences physiological, physical and behavioral aspects which could be detected through the personal digital algorithm and could prevent psychiatric deterioration. For example, in a case of a person in a manic episode investigators would expect to find changes in the personal digital algorithm in physiological aspects(increased heart rate, elevated Heart Rate Variability), physical aspects such as increased number of steps per day, and behavioral aspects(increased hours spent outside of home, excessive activity). An early detection can help in the prevention of psychiatric deterioration in this case and help minimize the suffering caused to the patient and caregivers and perhaps assist in minimizing the need for hospitalization.

The data will be collected using wrist watches. The sensors will collect the physiological data(Heart Rate Variability), physical data(number of steps per day) and the behavioral data(quality of sleep). This data will then be collected and analyzed through big data analysis.
OBJECTIVES: This study aimed to determine agreement between reported percentage pain reduction (RPPR) and calculated percentage pain reduction (CPPR) in patients with percutaneous spinal cord stimulation (SCS) implants, and to correlate RPPR and CPPR with patient satisfaction. We also sought to determine which patient-reported outcome measures are most improved in patients with SCS.
MATERIALS AND METHODS: Fifty patients with percutaneous spinal cord stimulator implants with a mean follow-up of 51.1 months were interviewed and surveyed to assess their pain level, impression of degree of pain relief, satisfaction with the therapy, and desire to have the device again. Baseline pain level was obtained from their preimplant records.
RESULTS: Overall, RPPR was found to be 53.3%, whereas CPPR was 44.4%. Of all patients, 21 reported <50% pain reduction; however, most of these (12/21, 57%) were satisfied with the outcome of therapy. In terms of individual improvement in outcomes, activities of daily life was the most improved measure at 82%, followed by mood, sleep, medication use, and health care utilization at 74%, 62%, 50%, and 48%, respectively.
CONCLUSIONS: RPPR appears to be a complex outcome measure that may not agree with CPPR. Overall RPPR is greater than the CPPR. On the basis of our data, these independently valid measures should not be used interchangeably. A 50% pain reduction threshold is not a requisite for patient satisfaction and desire to have the device again. Activities of daily living was the most improved measure in this cohort, followed by mood, sleep, medication usage, and decrease in health care utilization.
On 35 strains of Helicobacer pylori it was proven using thedisc method that the Bulgarian attar of roses has good inhibitioneffect in respect of bacteria. Inhibiting effect also belongs tothe geraniol alcohol contained in the attar whilst their solventcremophor EL does not demonstrate such qualities. The inhibitioneffect is manifested both in respect of the inhibition zones andthe percentage of inhibited strains, 12.2 mm for the attar ofroses and 13.4 mm for the geraniol (average diameter),respectively, and 74% inhibition for the attar of roses and 76%for the geraniol, and also in respect of the determined MIC. Ithas been calculated that MIC90 of the attar of roses and geraniolis approximately 1 mg/l by which they are superior both to MIC ofthe bismuth salts and to MIC of some antibacterial agents(metronidazole, clindamycin, nalidicidic acid, oxacylin andothers). Improved inhibiting potentials belongs only tocyprophloxacyn, amoxycylin, tetracyline and oxacyline. The solventof cremophore EL has no inhibition effect.
Status epilepticus (SE) carries risks of morbidity and mortality. Experimental studies have implicated the entorhinal cortex in prolonged seizures; however, studies in large human cohorts are limited. We hypothesised that individuals with temporal lobe epilepsy (TLE) and a history of SE would have more severe entorhinal atrophy compared to others with TLE and no history of SE. 357 individuals with drug resistant temporal lobe epilepsy (TLE) and 100 healthy controls were scanned on a 3T MRI. For all subjects, the cortex was segmented, parcellated, and the thickness calculated from the T1-weighted anatomical scan. Subcortical volumes were derived similarly. Cohen's d and Wilcoxon rank-sum tests respectively were used to capture effect sizes and significance. Individuals with TLE and SE had reduced entorhinal thickness compared to those with TLE and no history of SE. The entorhinal cortex was more atrophic ipsilaterally (d = 0.51, p < 0.001) than contralaterally (d = 0.37, p = 0.01). Reductions in ipsilateral entorhinal thickness were present in both left TLE (n = 22:176, d = 0.78, p < 0.001), and right TLE (n = 19:140, d = 0.31, p = 0.04), albeit with a smaller effect size in right TLE. Several other regions exhibited atrophy in individuals with TLE, but these did not relate to a history of SE. These findings suggest potential involvement or susceptibility of the entorhinal cortex in prolonged seizures.
Like other topical corticosteroids, betamethasone valerate foam has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Pharmacokinetics:

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. They are metabolized, primarily in the liver, and are then excreted by the kidneys. In addition, some corticosteroids and their metabolites are also excreted in the bile.
PURPOSE: To obtain a drug-effect substance from balsam pear or balsam pear seed. CONSTITUTION: Balsam pear, balsam pear seed or balsam pear sprout produced by germinating balsam pear seed is used as a raw material for the objective substance. The raw material is crushed, heated in distilled water to decoct the active component and further heated to obtain a concentrated drug-effect substance in liquid or pasty state. The product may be further heated and dried to a powdery or granular drug-effect substance. A squash-type protease inhibitor existing in the drug-effect substance directly dissolves in blood to inhibit the blood coagulation and exhibit the treating and preventing effect on thrombotic diseases such as cerebral infarction and myocardial infarction. It is also effective for getting a slim body since the substance acts as an inhibitor of digestive enzymes such as trypsin in the intestine.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine. The polymeric particles containing active substance for release of active substances, containing vinyl polymerisation product from 10-80 wt % are described; containing amino - and-or carboxyl groups of monomers, 20-90 wt % of compound alkyl ethers of acrylic and-or methacrylic acids which is insoluble in a part of pH in 0-10 range and soluble in other part of the range, and these polymeric particles containing active substance in the form of water dispersion - contain 3-1000 parts of active substance per one part of vinyl polymerisation product, - have the size of particles in a range of 20 nanometers - 8 microns and - vinyl polymerisation product on >50 wt % is constructed of polymers with molecular weight <100.000 dalton. The invention is referred on the aimed release of liquid active substances. ^ EFFECT: provision of aimed release of liquid operating substances. ^ 7 cl, 5 ex
This invention relates to novel indazole derivatives of formula (I), wherein R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be use as medicaments. The compounds are selective modulators of the farnesoid-X-receptor, preferably agonists the farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. Diseases which are affected by FXR modulators include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, diseases of cholesterol absorption, atherosclerotic disease, peripheral occlusive disease, ischemic, stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, diabetic nephropathy, obesity, cholesterol gallstone disease, cholestasis/fibrosis of the liver, non alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), psoriasis, cancer, particularly gastrointestinal cancer, osteoporosis, Parkinson's disease and Alzheimer's disease. Preferred diseases (and conditions) which are affected by FXR modulators are prevention or treatment of high LDL cholesterol levels high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome. Particularly preferred diseases which arc affected by FXR modulators arc high LDL cholesterol, high triglyceride levels and dyslipidemia.
Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
OBJECTIVE: This study aimed to present 2 children clinically diagnosed with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome and treated with intracapsular tonsillectomy with adenoidectomy (ITA).
METHODS: We conducted a retrospective analysis of 2 children who were referred for an otolaryngology consultation between 2019 and 2022 for surgical treatment of PFAPA syndrome. Both patients had symptoms strongly suggestive of PFAPA and were at risk for total tonsillectomy (TT) complications. ITA was performed using a microdebrider. Both patients were followed up postoperatively to assess for symptomatic resolution and complications.
RESULTS: Two children exhibited recurrent febrile episodes prior to ITA. The procedure was efficacious in both patients, with neither experiencing postoperative complications or recurring PFAPA symptoms for over 1 year after surgery.
CONCLUSION: Our study reported on the use of ITA as a surgical treatment option for PFAPA. We showed that ITA eliminated febrile attacks and was safely performed without postoperative complications in 2 pediatric patients after 1-year follow-up. Future studies involving larger cohorts of PFAPA patients and lengthier follow-ups will need to be conducted to further evaluate ITA as a surgical option. Laryngoscope, 134:1967-1969, 2024.
The invention discloses a lactone compound of false Chinese swertia herb, as well as a preparation method, a preparation and an application of the lactone compound. The lactone compound of the false Chinese swertia herb is prepared from swertiamarin as a raw material. A molecular formula of the lactone compound is C18H20O6. The lactone compound has the following structural formula as shown in the specification. The preparation method comprises the steps of separating and purifying a swertiamarin thermal conversion product by a reverse medium-pressure column method, an MCI-GEL method, a silica gel method and the like to prepare the lactone compound. Pharmacological studies show that the lactone compound has a significant liver protection effect and hepatits B virus activity resistance at the same time. The preparation method has the advantages that a raw material is sufficient in source and easy to obtain, the technology is simple, and the method can be used for industrial production.
A multi-centre, double-blind, placebo controlled, randomized, parallel group, dose ranging study to investigate the efficacy and tolerability of two different target doses of tonabersat and placebo in the prophylaxis of migraine. Following initial screening patients will enter a 4 week baseline assessment period, prior to randomization to one of three treatment groups. Subsequently patients will be allocated, according to the predetermined randomization schedule, to treatment with placebo or a target dose of tonabersat 40 mg/day or 80 mg/day in a 20 week treatment period. A dose titration regimen will be employed over a period of 4 weeks and treatment will then be maintained for a further 16 weeks. During the baseline assessment period and the treatment period patients will maintain a daily record (diary data) of the occurrence of migraine headache, the severity of an attack, the presence/absence of a preceding aura, other symptoms associated with the migraine and details of the use of rescue medication (patients will be permitted to use their usual symptomatic/acute treatment as rescue medication throughout the trial). Patients will attend the clinic for assessment and collection of blood and urine samples for laboratory analysis, and a sub-population of patients will participate in a pharmacokinetic study. A total of 7 visits are planned during the randomized double-blind treatment period.

On completion of the randomized double-blind treatment period all patients will be offered the opportunity to enter an open label extension study where all patients receive tonabersat. A dose titration regimen will be employed over a period of 1 month and the final assigned dose of tonabersat (40, 60 or 80 mg/day) will be continued for the next 12 months. During the open label extension patients will attend the clinic for regular assessment of migraine status and safety. A total of 5 visits are planned.
This group of participants will be assigned to the intervention of HEPA filtration with the capacity to reduce indoor PM2.5 levels at their residence for 9 months first. After 3-month wash-out period, participants will be assigned to sham filters (air purifier has the same appearance but HEPA filter is removed) for 9 months.
On site visit every 6 months. Monthly remote PROMs evaluation + portable spirometer measurement to remotely monitor the disease.
Participants will receive an infrared therapy device for use at home for 60 days. Participants will use the device every day for 10-20 minutes during the intervention period.
The invention belongs to the field of biological medicine, and provides an application of a colorectal cancer synthetic lethal gene combination based on TP53 gene defects, which is used for accurately treating colorectal cancer carrying TP53 mutation. The synthetic lethal gene pair consists of TP53 and USP1 genes, and is based on machine learning prediction and molecular cell biology experiment verification. The invention discovers that the synthetic lethal gene pair TP53 and USP1 can be used for treating colorectal cancer for the first time. It was verified that the synthesis of lethal gene pairs using TP53 and USP1 can effectively kill colorectal cancer cells without damaging normal cells. In addition, based on the gene pair, medicaments for treating colorectal cancer can be prepared and developed. The invention provides a new method for developing colorectal cancer treatment on a molecular level, and provides a new target point for drug development of colorectal cancer treatment.
Composition for treating impaired lactation is described according to the preferred embodiment of the teachings of the present invention for oral administration to swine. The composition according to the teachings of the present invention includes blood albumin meal to provide a rich source of nutrients such as amino acids. Blood albuin helps insure that the osmotic pressure of the blood and interstitial tissue fluid around the mammary gland alveoli is optimized. Psyllium seed is further provided in the composition according to the teachings of the present invention as a natural laxative and as an effective aid in the treatment of constipation. Specifically, an oily, mucilaginous mass is formed when the psyllium seed comes in contact with water or fluid in the digestive tract and lubricates the digestive tract to help stimulate evacuations. The composition according to the teachings of the present invention includes an electrolyte base to help eliminate fluid and electrolyte imbalances in the tissues that may lead to excessive udder edema and caking. The treatment composition of the present invention provides a slow, gentle anticonstipating action in a palatable manner for maintaining a good appetite with less signs of constipation and for maintaining optimum milk production with less signs of udder edema and caking.